US 12,458,623 B2
Low-grade inflammation compositions
V. A. Shiva Ayyadurai, Cambridge, MA (US); and Prabhakar Deonikar, Cambridge, MA (US)
Assigned to CytoSolve, Inc., Cambridge, MA (US)
Filed by CytoSolve, Inc., Cambridge, MA (US)
Filed on Mar. 17, 2023, as Appl. No. 18/123,128.
Claims priority of provisional application 63/321,544, filed on Mar. 18, 2022.
Prior Publication US 2023/0293484 A1, Sep. 21, 2023
Int. Cl. A61K 31/353 (2006.01); A61K 9/00 (2006.01); A61K 31/01 (2006.01); A61K 31/07 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 9/0053 (2013.01); A61K 31/01 (2013.01); A61K 31/07 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61P 29/00 (2018.01)] 4 Claims
 
1. A composition comprising:
about 0.7% w/w of (−)-epicatechin;
about 0.04% w/w of EGCG;
about 1.6% w/w of lycopene;
about 0.6% w/w of quercetin;
about 0.04% w/w of luteolin;
about 4.3% w/w of vitamin A;
about 61% w/w of vitamin C; and,
about 26.82% w/w of vitamin E.